We therefore assessed the efficacy of COTI-2 against multiple human cancer cell lines representing common human malignancies, allowing assessment of effectiveness of COTI-2 in cell lines with various mutations including; TP53 (HT-29, HCT-15, OVCAR-3, K562, SF-268, SNB-19, T47D, MDA-MB-231), KRAS (MDA-MB-231, SW620), PIK3CA (MCF7, HT-29, T47D), APC (COLO-205, HCT-15), and PTEN (SF-295, SNB-19) [25]. The gene discussed is KRAS; the disease is cancer.